MoonLake Immunotherapeutics Reports Full Year 2024 Financial Results and Provides a Business Update Post date February 26, 2025 ← MoonLake initiates three new clinical trials and further expands the portfolio of indications for the Nanobody® sonelokimab → MoonLake Secures up to $500 Million in Non-Dilutive Financing from Hercules Capital and Announces a Capital Markets Update on April 29 to Provide Important Clinical Updates
